High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation.

Abstract

Management of COVID-19 patients experiencing persisting respiratory failure despite corticosteroids remains challenging. Data on high-dose intravenous anakinra (HD-ANK) in this context are lacking. We aimed to investigate the impact of HD-ANK on mortality in COVID-19 patients progressing to non-invasive ventilation (NIV) while receiving corticosteroids. We retrospectively analyzed the impact of HD-ANK on 28-day mortality in individuals hospitalized with COVID-19 necessitating NIV after corticosteroid initiation. A total of 256 patients were identified: 146 received standard-of-care only (SOC), and 110 received HD-ANK+SOC. The groups were well-balanced at baseline. In-hospital mortality at 28 days did not differ between the two groups. HD-ANK is not beneficial in patients with severe COVID-19 deteriorating despite corticosteroids.

• Authors: Andrea Mastrangelo, Roberta Monardo, Laura Galli, Alessandro Tomelleri, Chiara Tassan Din, Diana Canetti, Emanuela Messina, Monica Guffanti, Anna Danise, Corrado Campochiaro, Giulio Cavalli, Giacomo Monti, Paola Cinque, Paolo Scarpellini, Giovanni Landoni, Fabio Ciceri, Lorenzo Dagna, Antonella Castagna, Marco Ripa
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 42 Issue 11 Pg. 1383-1387 (Nov 2023) ISSN: 1435-4373 [Electronic] Germany
• PMID: 37723323 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.